Abstract

Simple SummaryHepatocellular carcinoma (HCC) is one of the deadliest human health burdens worldwide. However, the molecular mechanism of HCC development is still not fully understood. Sex determining region Y-related high-mobility group box (SOX) transcription factors not only play pivotal roles in cell fate decisions during development but also participate in the initiation and progression of cancer. Given the significance of SOX factors in cancer and their ‘undruggable’ properties, we summarize the role and molecular mechanism of SOX family members in HCC and the regulatory effect of SOX factors in the tumor immune microenvironment (TIME) of various cancers. For the first time, we analyze the association between the levels of SOX factors and that of immune components in HCC, providing clues to the pivotal role of SOX factors in the TIME of HCC. We also discuss the opportunities and challenges of targeting SOX factors for cancer.Sex determining region Y (SRY)-related high-mobility group (HMG) box (SOX) factors belong to an evolutionarily conserved family of transcription factors that play essential roles in cell fate decisions involving numerous developmental processes. In recent years, the significance of SOX factors in the initiation and progression of cancers has been gradually revealed, and they act as potential therapeutic targets for cancer. However, the research involving SOX factors is still preliminary, given that their effects in some leading-edge fields such as tumor immune microenvironment (TIME) remain obscure. More importantly, as a class of ‘undruggable’ molecules, targeting SOX factors still face considerable challenges in achieving clinical translation. Here, we mainly focus on the roles and regulatory mechanisms of SOX family members in hepatocellular carcinoma (HCC), one of the fatal human health burdens worldwide. We then detail the role of SOX members in remodeling TIME and analyze the association between SOX members and immune components in HCC for the first time. In addition, we emphasize several alternative strategies involved in the translational advances of SOX members in cancer. Finally, we discuss the alternative strategies of targeting SOX family for cancer and propose the opportunities and challenges they face based on the current accumulated studies and our understanding.

Highlights

  • Transcription factors (TFs) are one of the most pivotal sequence-specific DNA-binding proteins responsible for decoding DNA sequences

  • In order to accomplish the transcriptional regulation of genes, TFs require at least one DNA-binding domain (DBD) for recognizing and binding specific DNA sites located in promoters or enhancers/silencers of targeted genes and another effector domain for recruiting transcriptional machinery to DNA [1]

  • SOX9 binds to the enhancer of INHBB and induces its expression, thereby increasing the secretion of activin B from hepatocellular carcinoma (HCC) cells into the microenvironment, leading to the activation of peri-tumoral Hepatic stellate cells (HSCs) mediated by activin B/Smad signaling and subsequently promoting liver fibrosis and metastasis of HCC [108]

Read more

Summary

Introduction

Transcription factors (TFs) are one of the most pivotal sequence-specific DNA-binding proteins responsible for decoding DNA sequences. In order to accomplish the transcriptional regulation of genes, TFs require at least one DNA-binding domain (DBD) for recognizing and binding specific DNA sites located in promoters or enhancers/silencers of targeted genes and another effector domain for recruiting transcriptional machinery to DNA [1] To this point, over 2000 TFs divided into various families based on the homologous DBDs have been identified, many of which enable the controlling of some critical biological processes in a way that depends on cell type and development patterning [2]. The genes encoding TFs produce fusion proteins with functional alteration due to frequent chromosomal translocations such as PLZF-RARα [5] These abnormal TFs fusion products disrupt the transcriptional networks during the specific periods of hematopoietic cell differentiation and cause the initiation of cancer [5]. We emphasize several alternative strategies involved in the translational advances of SOX members in cancer, and discuss the opportunities and challenges of targeting the SOX family in cancer based on the current accumulated studies and on our understanding

Overview of the SOX Transcription Factors
SOX A (SRY)
SOX B1 and SOX B2 (SOX1, SOX2, SOX3, SOX14, and SOX21)
SOX C (SOX4, SOX11, and SOX12)
SOX D (SOX5, SOX6, SOX13, and SOX23)
SOX E (SOX8, SOX9, and SOX10)
SOX F (SOX7, SOX17, and SOX18) and SOX H (SOX30)
SOX Transcription Factors and Tumor Immune Microenvironment
The Role of SOX in Tumor Immune Microenvironment
Association between the Expression of SOX and That of Immune Components in Hepatocellular Carcinoma
SOX Transcription Factors and Translational Potential
SOX Factors as Biomarkers for Patient Stratification Treatment
Targeting SOX Proteins Degradation
SOX Factors as Peptide Vaccine Boost Anti-Tumor Immune Response
Tumor-Targeted Delivery of siRNA to Silence SOX Expression
Targeting Endogenous SOX Expression by Artificial Transcription Factors-Based Technologies
Findings
Discussion and Outlook
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call